Also trades as: SLXNW (NASDAQ) · $vol 0M
SLXN NASDAQ
Silexion Therapeutics Ltd.
1W: -0.1%
1M: -26.0%
3M: -90.9%
YTD: -86.2%
1Y: -93.1%
$0.26
-0.02 (-6.85%)
Weekly Expected Move ±34.0%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$14K
+0.0% ▲
Operating Income
-$12M
+7.5% ▲
Net Income
-$12M
+27.6% ▲
EPS (Diluted)
$-8.96
-239.4% ▼
EBITDA
-$12M
+29.5% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $14K |
| Gross Profit | $0 | $0 | $0 | $0 | -$14K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $0 | $3M | $4M | $6M | $7M |
| SG&A Expenses | $944K | $577K | $928K | $7M | $4M |
| Operating Expenses | $944K | $4M | $5M | $13M | $12M |
| Operating Income | -$944K | -$4M | -$5M | -$13M | -$12M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $85K | $9K | $52K | $0 |
| Income Before Tax | -$755K | -$3M | -$5M | -$17M | -$12M |
| Tax Expense | $0 | $24K | $32K | $10K | $3K |
| Net Income | -$755K | -$3M | -$5M | -$16M | -$12M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-0.05 | $0.03 | $-4.42 | $-2.64 | $-8.96 |
| EBITDA | -$755K | -$4M | -$5M | -$16M | -$12M |
| Shares Outstanding | 17M | 17M | 1M | 6M | 1M |